You are right, but regulatory capture and anti-trust are two separate things.

Pharma does not on its face meet the definition of a monopoly. There are numerous companies, of varying sizes, and they compete with one another. They use tactics like patents to enjoy for a limited time monopolistic pricing, but the patent system makes this tradeoff intentionally, in the interest of broad publication of research and knowledge.

Pharma benefits greatly from regulatory capture. This has never been more obvious than in the C19 kerfuffle.

I suspect that pharma (and its corrupt 'regulators') will get some sort of comeuppance in the years to follow, though I have no idea what that will look like.